-
Mashup Score: 1Novel Treatment Options for BCG Naïve Non-Muscle Invasive Bladder Cancer: Immune Priming and Immune Check Point Inhibitors - 6 month(s) ago
bladder cancer, Bacillus Calmette-Guerin (BCG), BCG treatment, BCG Naïve Non-Muscle Invasive Bladder Cancer, non muscle invasive bladder cancer (NMIBC), KEYNOTE-057trial, Novel Treatment Options for BCG Naïve Non-Muscle Invasive Bladder, Immune Priming, Immune Check Point Inhibitors, KEYNOTE-676 trial, trans urethral resection of bladder tumor (TURBT), Pembrolizumab, Atezolizumab, Durvalumab, metastatic urothelial carcinoma of the bladder, Sasanlimab, POTOMAC study, NCT03504163.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Novel Treatment Options for BCG Naïve Non-Muscle Invasive Bladder Cancer: Intravesical Chemotherapy - 6 month(s) ago
urothelial cancer of the bladder, bladder cancer, Bacillus Calmette-Guerin (BCG), BCG treatment, BCG naive non muscle invasive bladder cancer, transurethral resection of bladder tumor (TURBT), Novel Treatment Options for BCG Naïve Non-Muscle Invasive Bladder Cancer, Intravesical Chemotherapy, electromotive mitomycin, CUETO 93009, Hyperthermic Intravesical Chemotherapy (HIVEC), gemcitabine, docetaxel.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 5
FDA approval of pembrolizumab for BCG-unresponsive patients with NMIBC, Non-Muscle Invasive Bladder Cancer (NMIBC), BCG-unresponsive Non-Muscle Invasive Bladder Cancer, Immune Checkpoint Inhibitors, Pembrolizumab, KEYNOTE-057 trial, intravenous pembrolizumab.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0The Impact of Surgeon Experience and Volume on Patient Outcomes in Radical Prostatectomy Patients - 7 month(s) ago
radical prostatectomy, robotic-assisted laparoscopic, prostate cancer, National Health Service (NHS), cancer surgery experience, cancer surgery outcome ratios, surgery volume in prostate cancer, minimally invasive techniques for prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Artificial intelligence for prostate cancer, prostate cancer, androgen deprivation therapy, artificial intelligence for risk stratification after primary therapy, radical prostatectomy, Radiotherapy, Machine learning for prostate cancer, NRG/RTOG 9408 trial, Artera AI.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 6The Impact of Surgeon Experience and Volume on Patient Outcomes in Radical Prostatectomy Patients - 8 month(s) ago
radical prostatectomy, robotic-assisted laparoscopic, prostate cancer, National Health Service (NHS), cancer surgery experience, cancer surgery outcome ratios, surgery volume in prostate cancer, minimally invasive techniques for prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Artificial intelligence for prostate cancer, prostate cancer, androgen deprivation therapy, artificial intelligence for risk stratification after primary therapy, radical prostatectomy, Radiotherapy, Machine learning for prostate cancer, NRG/RTOG 9408 trial, Artera AI.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Prostate Radiotherapy for De Novo, Low Volume Metastatic Hormone Sensitive Prostate Cancer: Is There Benefit? - 9 month(s) ago
prostate radiotherapy in the de novo mHSPC setting, metastatic hormone-sensitive prostate cancer (mHSPC) with low-volume disease per conventional imaging, prostate cancer radiotherapy, metastatic hormone sensitive prostate cancer, (mHSPC), PEACE-1 trial, STAMPEDE trial, HORRAD study
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 6
Artificial intelligence for prostate cancer, prostate cancer, androgen deprivation therapy, artificial intelligence for risk stratification after primary therapy, radical prostatectomy, Radiotherapy, Machine learning for prostate cancer, NRG/RTOG 9408 trial, Artera AI.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations: Will This Be The Future of mCRPC First-Line Therapy? - 9 month(s) ago
PARPi plus androgen receptor signaling inhibitor, metastatic castrate-resistant prostate cancer (mCRPC), PROpel, MAGNITUDE, TALAPRO-2, imaging-based progression-free survival, PARPi plus an ARSI in the first-line treatment setting for mCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PARP inhibitor + AR signaling inhibitor combinations: Will this be the future of #mCRPC first-line therapy? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss data from the #PROpel, #MAGNITUDE, and #TALAPRO2 trials on UroToday > https://t.co/Lel4jqTXoV https://t.co/7xe3Vo9AtU
-
Novel treatment options for BCG naïve nonmuscle-invasive #BladderCancer: immune priming and immune checkpoint inhibitors. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss the current state of the evidence for ongoing trials > https://t.co/zGyYh3Yqwi https://t.co/MkbJ4w4yGl